Chronic Lymphocytic Leukemia Therapy
Reports outline chronic lymphocytic leukemia therapy research from Mayo Clinic, Division of Hematology
Published in Blood Weekly, December 18th, 2008
New research, 'Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab,' is the subject of a report. According to a study from the United States, "The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) is not well understood. We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance."
"Alemtuzumab had minimal direct cytotoxicity but caused significant complement dependent cytotoxicity...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-12-18)
More Articles from Blood Weekly
- Canadian Medical Association Journal
Risk of death may be higher with drug commonly used during cardiac surgery - Johns Hopkins Medical Institutions
Fruit fly discovery generates buzz about brain-damaging disorder in children - University of Rochester Medical Center
Mini heart attacks lessen damage from major ones - Worcester Polytechnic Institute
Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants - Afibrinogenemia
New afibrinogenemia data have been reported by scientists at Cornell University - Autoimmune Hemolytic Anemia
Research reports on autoimmune hemolytic anemia from L. Shvidel and colleagues provide new insights - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
